Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients-Reference-Cited by-同舟云学术

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Published:2015-12-21 Issue:3 Volume:5 Page:e1094598
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hong Shaodong,Chen Nan,Fang Wenfeng,Zhan Jianhua,Liu Qing,Kang Shiyang,He Xiaobo,Liu Lin,Zhou Ting,Huang Jiaxing,Chen Ying,Qin Tao,Zhang Yaxiong,Ma Yuxiang,Yang Yunpeng,Zhao Yuanyuan,Huang Yan,Zhang Li

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1094598

Reference32 articles.

1. Cancer statistics, 2014

2. Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?

3. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

4. A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population

5. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial;JTO Clinical and Research Reports;2024-07

2. Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients;Thoracic Cancer;2024-03-08

3. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer;Frontiers in Immunology;2024-02-15

4. Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy;Journal of Biomedical Science;2024-01-29

5. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27